Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta-analysis


Clinical Question: What are the benefits and harms of perioperative pharmacological thromboprophylaxis in cancer patients undergoing surgery?

Background: Both cancer and surgery increase the risk of venous thromboembolism (VTE). In postsurgical patients with cancer, the benefits and harms of anticoagulation remain unknown.

Study Design: Systematic review and meta-analysis.

Synopsis: Thirty-nine trials were deemed eligible for inclusion in the meta-analysis. Twenty-five of these were prospective and 14 were retrospective. The overall incidence of deep venous thrombosis (DVT) and pulmonary embolism was 0.9% (across 20 studies) and 0.3% (across 19 studies), respectively. Pharmacologic prophylaxis overall reduced DVT incidence (0.5% vs. 1.2%; relative risk, 0.51; P = .03). Subgroup analysis demonstrated this was significant for abdominal/pelvic surgeries and with low molecular weight heparin. Six studies compared duration of standard prophylaxis (10 days) with extended prophylaxis (4 weeks), with a lower VTE rate in the extended group. Bleeding events were noted in 13 studies and pharmacologic prophylaxis significantly increased bleeding risk (2.7% vs. 8%; RR, 2.51; P less than .0001).

Bottom Line: Perioperative pharmacologic prophylaxis reduces DVT risk in patients with cancer, with greatest risk reduction seen in patients undergoing abdominal/pelvic surgeries. This comes at the cost of increased bleeding complications.

Citations: Guo Q, Huang B, Zhao J, et al. Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Ann Surg. 2016 Nov. doi: 10.1097/SLA.0000000000002074.

Dr. Patil is a clinical instructor, Division of Hospital Medicine, University of Colorado School of Medicine, Aurora.

Recommended Reading

First-in-kind study parsed risks of central lines in children
The Hospitalist
Hospital-acquired VTE with high risk of recurrence
The Hospitalist
Evidence suggests fondaparinux is more effective than LMWH in prevention of VTE and total DVT in the postoperative setting
The Hospitalist
DVT prophylaxis not needed after casting
The Hospitalist
Anticoagulants: more harm than good in isolated calf DVT
The Hospitalist
Prevalence of pulmonary embolism among syncope patients
The Hospitalist
Recent increase in subdural hematoma may be linked to antithrombotics
The Hospitalist
A little rivaroxaban goes a long way
The Hospitalist
   Comments ()